National Clinical Trials Network (NCTN) group focused on improving outcomes for adults with cancer through multi-center clinical research, recently announced changes in leadership across multiple ...

Pivotal Phase 3 trial of MO-03 builds on prior studies that demonstrated enhanced immunotherapy benefit without added ...

BostonGene has entered a new collaboration with AstraZeneca to apply its foundation AI model to oncology drug development, aiming to improve early trial decision-making around safety, efficacy, and ...

Natera, Inc. (NASDAQ:NTRA) is one of the High Growth Large Cap Stocks to Buy Right Now. On December 18, the company announced publication of the findings from the randomized, phase III CALGB (Alliance ...

Bristol-Myers Squibb Company (NYSE: BMY) is one of the cheap stocks to buy for the next 3 years. On January 9, Scotiabank ...

Protege, an AI data platform unlocking access to trusted, real-world data at scale, today announced a $30 million Series A round led by Andreessen Horowitz (a16z). The financing expands the company's ...

A new survey from AIResumeBuilder.com reveals that 9 in 10 Gen Zers say they're reliant on ChatGPT and similar conversational AI tools, suggesting that conversational AI may now be as essential to ...

Patient-reported fatigue prior to cancer treatment could be used as a biomarker for identifying which individuals will develop serious or fatal adverse events.A retrospective analysis showed patients ...

Investigators explored the association between baseline patient-reported fatigue and the risk adverse events in cancer treatment trials.

Based on phase 3 trial data, the FDA accepted an sBLA for nivolumab plus AVD for untreated stage III or IV classical Hodgkin lymphoma.

Higher levels of pre-existing fatigue in cancer patients correlated with greater risk of experiencing severe or worse toxic effects when receiving systemic therapy, according to pooled trial analysis.